CoChat

Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis

Zakhour, Johnny, Sharara, Sima L., Hindy, Joya-Rita, Haddad, Sara F., Kanj, Souha S. · 2022 · Antibiotics
Cited by 48

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Pseudomonas aeruginosa is a pathogen often encountered in a healthcare setting. It has consistently ranked among the most frequent pathogens seen in nosocomial infections, particularly bloodstream and respiratory tract infections. Aside from having intrinsic resistance to many antibiotics, it rapidly acquires resistance to novel agents. Given the high mortality of pseudomonal infections generally, and pseudomonal sepsis particularly, and with the rise of resistant strains, treatment can be very challenging for the clinician. In this paper, we will review the latest evidence for the optimal treatment of P. aeruginosa sepsis caused by susceptible as well as multidrug-resistant strains including the difficult to treat pathogens. We will also discuss the mode of drug infusion, indications for combination therapy, along with the proper dosing and duration of treatment for various conditions with a brief discussion of the use of non-antimicrobial agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antibiotics11101432

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 148

  1. Fosse, 2018, Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections, PLoS ONE, 13, e0203295, 10.1371/journal.pone.0203295 · DOI
  2. Horino, 2012, Clinical characteristics and risk factors for mortality in patients with bacteremia caused by Pseudomonas aeruginosa, Intern. Med. Tokyo Jpn., 51, 59, 10.2169/internalmedicine.51.5698 · DOI
  3. Kang, 2003, Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Influence of Delayed Receipt of Effective Antimicrobial Therapy on Clinical Outcome, Clin. Infect. Dis., 37, 745, 10.1086/377200 · DOI · Paper page
  4. Thaden, 2017, Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria, Antimicrob. Agents Chemother., 61, e02671-16, 10.1128/AAC.02671-16 · DOI · Paper page
  5. Cattaneo, 2012, P. aeruginosa bloodstream infections among hematological patients: An old or new question?, Ann. Hematol., 91, 1299, 10.1007/s00277-012-1424-3 · DOI
  6. Tofas, 2017, Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: Risk factors, treatment and outcome, Diagn. Microbiol. Infect. Dis., 88, 335, 10.1016/j.diagmicrobio.2017.05.003 · DOI
  7. Botelho, 2019, Antibiotic resistance in Pseudomonas aeruginosa—Mechanisms, epidemiology and evolution, Drug Resist. Updates, 44, 100640, 10.1016/j.drup.2019.07.002 · DOI · Paper page
  8. Babich, 2020, Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: A retrospective multicentre study, Int. J. Antimicrob. Agents, 55, 105847, 10.1016/j.ijantimicag.2019.11.004 · DOI
  9. Albasanz-Puig, A., Durà-Miralles, X., Laporte-Amargós, J., Mussetti, A., Ruiz-Camps, I., Puerta-Alcalde, P., Abdala, E., Oltolini, C., Akova, M., and Montejo, J.M. (2022). Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia. Microorganisms, 10. · DOI
  10. Nakamura, 2013, Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa, J. Hosp. Infect., 83, 153, 10.1016/j.jhin.2012.10.005 · DOI
  11. Aloush, 2006, Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact, Antimicrob. Agents Chemother., 50, 43, 10.1128/AAC.50.1.43-48.2006 · DOI · Paper page
  12. Mendelson, 1994, Pseudomonas aeruginosa bacteremia in patients with AIDS, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 18, 886, 10.1093/clinids/18.6.886 · doi:10.1093/clinids/18.6.886
  13. Flores, 1993, Bacteremia due to Pseudomonas aeruginosa in children with AIDS, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 16, 706, 10.1093/clind/16.5.706 · doi:10.1093/clind/16.5.706
  14. Zidaru, 2022, Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection, J. Glob. Antimicrob. Resist., 29, 551, 10.1016/j.jgar.2021.12.004 · doi:10.1016/j.jgar.2021.12.004
  15. Micek, 2015, An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: Impact of multidrug resistance, Crit. Care Lond. Engl., 19, 219, 10.1186/s13054-015-0926-5 · DOI · Paper page
  16. Tumbarello, 2013, Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients, Intensive Care Med., 39, 682, 10.1007/s00134-013-2828-9 · DOI · Paper page
  17. Bassetti, 2018, How to manage Pseudomonas aeruginosa infections, Drugs Context, 7, 212527, 10.7573/dic.212527 · DOI · Paper page
  18. Jabbour, 2020, Treatment of multidrug-resistant Gram-negative skin and soft tissue infections, Curr. Opin. Infect. Dis., 33, 146, 10.1097/QCO.0000000000000635 · DOI
  19. Ibrahim, 2020, Current choices of antibiotic treatment for Pseudomonas aeruginosa infections, Curr. Opin. Infect. Dis., 33, 464, 10.1097/QCO.0000000000000677 · DOI
  20. Herrera, 2021, Predictors of multidrug resistant Pseudomonas aeruginosa involvement in bloodstream infections, Curr. Opin. Infect. Dis., 34, 686, 10.1097/QCO.0000000000000768 · DOI
  21. Forkner, 1958, Pseudomonas septicemia; observations on twenty-three cases, Am. J. Med., 25, 877, 10.1016/0002-9343(58)90060-3 · doi:10.1016/0002-9343(58)90060-3
  22. Bassetti, 2016, Bloodstream infections in the Intensive Care Unit, Virulence, 7, 267, 10.1080/21505594.2015.1134072 · DOI
  23. Kaye, 2013, Carbapenem-resistant Enterobacteriaceae: A review of treatment and outcomes, Diagn. Microbiol. Infect. Dis., 75, 115, 10.1016/j.diagmicrobio.2012.11.009 · DOI · Paper page
  24. Falcone, 2020, Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae, Crit. Care Lond. Engl., 24, 29, 10.1186/s13054-020-2742-9 · DOI · Paper page
  25. Kaprou, G.D., Bergšpica, I., Alexa, E.A., Alvarez-Ordóñez, A., and Prieto, M. (2021). Rapid Methods for Antimicrobial Resistance Diagnostics. Antibiotics, 10. · DOI · Paper page
  26. Bassetti, 2018, Rational approach in the management of Pseudomonas aeruginosa infections, Curr. Opin. Infect. Dis., 31, 578, 10.1097/QCO.0000000000000505 · DOI
  27. Rosenthal, 2016, International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module, Am. J. Infect. Control, 44, 1495, 10.1016/j.ajic.2016.08.007 · DOI · Paper page
  28. Kadri, 2018, Difficult-To-Treat Resistance in Gram-Negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-Line Agents, Clin. Infect. Dis., 67, 1803
  29. Paul, 2022, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine), Clin. Microbiol. Infect., 28, 521, 10.1016/j.cmi.2021.11.025 · DOI · Paper page
  30. Mulet, 2018, Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: Experience from the Balearic Islands, Eur. J. Clin. Microbiol. Infect. Dis., 37, 2191, 10.1007/s10096-018-3361-0 · DOI
  31. Vardakas, 2013, β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: A meta-analysis, Int. J. Antimicrob. Agents, 41, 301, 10.1016/j.ijantimicag.2012.12.006 · DOI
  32. Paul, 2014, Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis, Cochrane Database Syst. Rev., 2014, CD003344
  33. Peña, C., Suarez, C., Ocampo-Sosa, A., Murillas, J., Almirante, B., Pomar, V., Aguilar, M., Granados, A., Calbo, E., and Rodríguez-Baño, J. (2013). Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort. Clinical Infectious Diseases, Oxford Academic. Available online: https://academic.oup.com/cid/article/57/2/208/313652. · DOI · Paper page
  34. Onorato, 2022, Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: A meta-analysis, Int. J. Antimicrob. Agents, 59, 106512, 10.1016/j.ijantimicag.2021.106512 · DOI
  35. Micek, 2005, Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment, Antimicrob. Agents Chemother., 49, 1306, 10.1128/AAC.49.4.1306-1311.2005 · DOI · Paper page
  36. Fiore, M., Corrente, A., Pace, M.C., Alfieri, A., Simeon, V., Ippolito, M., Giarratano, A., and Cortegiani, A. (2022, July 31). Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis, Available online: https://pubmed.ncbi.nlm.nih.gov/33467508/. · doi:10.3390/antibiotics10010079
  37. Bassetti, 2020, Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: A consensus paper, Int. J. Antimicrob. Agents, 56, 106104, 10.1016/j.ijantimicag.2020.106104 · DOI
  38. Paulsson, 2017, Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: A retrospective cohort study, Eur. J. Clin. Microbiol. Infect. Dis., 36, 1187, 10.1007/s10096-017-2907-x · doi:10.1007/s10096-017-2907-x
  39. Puzniak, 2019, A Combination Antibiogram Evaluation for Pseudomonas aeruginosa in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals, Antimicrob. Agents Chemother., 63, e02564-18, 10.1128/AAC.02564-18 · DOI
  40. Wauters, 2018, Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: A randomised controlled trial, Int. J. Antimicrob. Agents, 51, 562, 10.1016/j.ijantimicag.2017.11.009 · DOI
  41. Moise, 2021, Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU, JAC-Antimicrob. Resist., 3, dlaa129, 10.1093/jacamr/dlaa129 · DOI
  42. Britt, 2018, Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis, Antimicrob. Agents Chemother., 62, e02400-17, 10.1128/AAC.02400-17 · DOI
  43. Kaye, 2006, Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 50, 2192, 10.1128/AAC.00060-06 · DOI
  44. McKeage, 2015, Finafloxacin: First global approval, Drugs, 75, 687, 10.1007/s40265-015-0384-z · doi:10.1007/s40265-015-0384-z
  45. Kocsis, B., Gulyás, D., and Szabó, D. (2021). Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics, 10. · DOI
  46. Gimeno, 2010, Grupo Español de Estudio de Doripenem [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study], Rev. Espanola Quimioter. Publicacion Of. Soc. Espanola Quimioter., 23, 144
  47. Pillar, 2008, In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States, Antimicrob. Agents Chemother., 52, 4388, 10.1128/AAC.00381-08 · DOI
  48. Korten, 2011, Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study, Mikrobiyol. Bul., 45, 197
  49. Kanj, 2011, Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa, Mayo Clin. Proc., 86, 250, 10.4065/mcp.2010.0674 · DOI · Paper page
  50. Carmeli, 1999, Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents, Antimicrob. Agents Chemother., 43, 1379, 10.1128/AAC.43.6.1379 · DOI
  51. Phe, 2019, Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia, Diagn. Microbiol. Infect. Dis., 93, 346, 10.1016/j.diagmicrobio.2018.10.019 · doi:10.1016/j.diagmicrobio.2018.10.019
  52. Varghese, J.M., Roberts, J.A., and Lipman, J. (2011). Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically Ill with Severe Sepsis and Septic Shock-Critical Care Clinics, Elsevier. Available online: https://www.criticalcare.theclinics.com/article/S0749-0704(10)00068-0/fulltext.
  53. Kluge, 1974, Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 6, 442, 10.1128/AAC.6.4.442 · doi:10.1128/aac.6.4.442
  54. Zhanel, 2012, Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin, Expert Rev. Anti Infect. Ther., 10, 459, 10.1586/eri.12.25 · DOI · Paper page
  55. Anderson, 2012, Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation, Infect. Control Hosp. Epidemiol., 33, 589, 10.1086/665721 · doi:10.1086/665721
  56. Riou, 2010, In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy, Int. J. Antimicrob. Agents, 36, 513, 10.1016/j.ijantimicag.2010.08.005 · DOI
  57. Rodrigues, 2016, Clinical and microbiological features of infections caused by Pseudomonas aeruginosa in patients hospitalized in intensive care units, Rev. Soc. Bras. Med. Trop., 49, 305, 10.1590/0037-8682-0446-2015 · doi:10.1590/0037-8682-0446-2015
  58. Peng, 2014, Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to health care–associated infection control in the hospitals of Southern China: A case-control surveillance study, Am. J. Infect. Control, 42, 1308, 10.1016/j.ajic.2014.08.006 · DOI
  59. Jeong, 2014, Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: Clinical impact of bacterial virulence and strains on outcome, Diagn. Microbiol. Infect. Dis., 80, 130, 10.1016/j.diagmicrobio.2014.07.003 · DOI
  60. Torrens, 2016, Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms, Antimicrob. Agents Chemother., 60, 6407, 10.1128/AAC.01282-16 · DOI
  61. Iregui, 2020, Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City, Microb. Drug Resist., 26, 722, 10.1089/mdr.2019.0298 · DOI
  62. Zamorano, 2020, Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants, Antimicrob. Agents Chemother., 64, e02165-19, 10.1128/AAC.02165-19 · DOI
  63. Doi, Y. (2019). Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clinical Infectious Diseases, Oxford Academic. Available online: https://academic.oup.com/cid/article/69/Supplement_7/S565/5623998. · DOI · Paper page
  64. Kollef, 2019, Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): A randomised, controlled, double-blind, phase 3, non-inferiority trial, Lancet Infect. Dis., 19, 1299, 10.1016/S1473-3099(19)30403-7 · DOI · Paper page
  65. Solomkin, 2015, Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI), Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 60, 1462, 10.1093/cid/civ097 · DOI · Paper page
  66. Wagenlehner, 2015, Ceftolozane-TAZOBACTAM Compared with Levofloxacin in the Treatment of Complicated Urinary-Tract Infections, Including Pyelonephritis: A Randomised, Double-Blind, Phase 3 Trial (ASPECT-cUTI), Lancet, 385, 1949, 10.1016/S0140-6736(14)62220-0 · DOI · Paper page
  67. Cabot, 2022, Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa, J. Antimicrob. Chemother., 77, 2809, 10.1093/jac/dkac241 · doi:10.1093/jac/dkac241
  68. Skoglund, 2018, In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways, Case Rep. Infect. Dis., 2018, 9095203
  69. Tamma, 2021, Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 73, e4599, 10.1093/cid/ciaa1306 · DOI
  70. Hamid, 2021, Clinical outcomes, molecular epidemiology and resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa isolated from bloodstream infections from Qatar, Ann. Med., 53, 2345, 10.1080/07853890.2021.2012588 · DOI
  71. Garazzino, 2020, Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data, Front. Pediatr., 8, 173, 10.3389/fped.2020.00173 · doi:10.3389/fped.2020.00173
  72. Pfaller, 2021, Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018, Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis., 112, 321
  73. Nichols, 2018, Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 62, e02590-17, 10.1128/AAC.02590-17 · doi:10.1128/aac.02590-17
  74. Teo, 2021, Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa, mSphere, 6, e01026-20, 10.1128/mSphere.01026-20 · DOI
  75. Bassetti, 2021, Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial, Lancet Infect. Dis., 21, 226, 10.1016/S1473-3099(20)30796-9 · DOI · Paper page
  76. Motsch, 2020, RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs. Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 70, 1799, 10.1093/cid/ciz530 · DOI · Paper page
  77. Pogue, 2020, Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 71, 304, 10.1093/cid/ciz816 · DOI · Paper page
  78. Karlowsky, 2017, In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015, Antimicrob. Agents Chemother., 61, e00472-17, 10.1128/AAC.00472-17 · DOI · Paper page
  79. Lee, 2021, Activity of aztreonam in combination with ceftazidime–avibactam against serine- and metallo-β-lactamase–producing Pseudomonas aeruginosa, Diagn. Microbiol. Infect. Dis., 99, 115227, 10.1016/j.diagmicrobio.2020.115227 · DOI
  80. Zhanel, 2019, Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli, Drugs, 79, 271, 10.1007/s40265-019-1055-2 · DOI · Paper page
  81. Kallel, 2006, Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU, Int. J. Antimicrob. Agents, 28, 366, 10.1016/j.ijantimicag.2006.07.008 · doi:10.1016/j.ijantimicag.2006.07.008
  82. Hanberger, 2011, When and How to Cover for Resistant Gram-Negative Bacilli in Severe Sepsis and Septic Shock, Curr. Infect. Dis. Rep., 13, 416, 10.1007/s11908-011-0200-1 · DOI
  83. Pontikis, 2014, Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria, Int. J. Antimicrob. Agents, 43, 52, 10.1016/j.ijantimicag.2013.09.010 · DOI · Paper page
  84. Barcenilla, 2007, Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy, Crit. Care Med., 35, 1888, 10.1097/01.CCM.0000275389.31974.22 · DOI · Paper page
  85. Carlier, 2013, Meropenem and piperacillin/tazobactam prescribing in critically ill patients: Does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?, Crit. Care Lond. Engl., 17, R84, 10.1186/cc12705 · DOI · Paper page
  86. Carlier, 2014, Extended versus bolus infusion of meropenem and piperacillin: A pharmacokinetic analysis, Minerva Anestesiol., 80, 1302
  87. Taccone, 2012, Optimal Meropenem Concentrations To Treat Multidrug-Resistant Pseudomonas aeruginosa Septic Shock, Antimicrob. Agents Chemother., 56, 2129, 10.1128/AAC.06389-11 · DOI
  88. Kuti, 2003, Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem, J. Clin. Pharmacol., 43, 1116, 10.1177/0091270003257225 · DOI · Paper page
  89. Kothekar, 2020, Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: Implications for empirical therapy against Gram-negative bacteria, Ann. Intensive Care, 10, 4, 10.1186/s13613-019-0622-8 · DOI
  90. Nasomsong, W., Nulsopapon, P., Changpradub, D., Pungcharoenkijkul, S., Hanyanunt, P., Chatreewattanakul, T., and Santimaleeworagun, W. (2022). Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa. Antibiotics, 11. · DOI
  91. Gatti, 2021, Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: A PK/PD approach to tailor dosing, J. Antimicrob. Chemother., 76, 199, 10.1093/jac/dkaa416 · DOI
  92. Ruiz, 2020, Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia, Dose-Response Publ. Int. Hormesis Soc., 18, 1559325819885790
  93. Xiao, 2016, Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia, J. Clin. Pharmacol., 56, 56, 10.1002/jcph.566 · DOI
  94. Lodise, 2007, Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 44, 357, 10.1086/510590 · DOI · Paper page
  95. Bauer, 2013, Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections, Antimicrob. Agents Chemother., 57, 2907, 10.1128/AAC.02365-12 · DOI
  96. Abrar, 2019, The pharmacodynamics of prolonged infusion blactams for the treatment of Pseudomonas aeruginosa infections: A systematic review, Clin. Ther., 41, 2397, 10.1016/j.clinthera.2019.09.010 · DOI
  97. Dulhunty, 2015, A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis, Am. J. Respir. Crit. Care Med., 192, 1298, 10.1164/rccm.201505-0857OC · DOI · Paper page
  98. Shiu, 2013, Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections, Cochrane Database Syst. Rev., 2013, CD008481
  99. Roberts, 2009, A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics, Crit. Care Med., 37, 2071, 10.1097/CCM.0b013e3181a0054d · DOI · Paper page
  100. Kasiakou, 2005, Continuous versus intermittent intravenous administration of antibiotics: A meta-analysis of randomised controlled trials, Lancet Infect. Dis., 5, 581, 10.1016/S1473-3099(05)70218-8 · DOI · Paper page
  101. Sulaiman, 2016, Beta-Lactam Infusion in Severe Sepsis (BLISS): A prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis, Intensive Care Med., 42, 1535, 10.1007/s00134-015-4188-0 · DOI · Paper page
  102. Dulhunty, 2013, Continuous infusion of beta-lactam antibiotics in severe sepsis: A multicenter double-blind, randomized controlled trial, Clin. Infect. Dis., 56, 236, 10.1093/cid/cis856 · DOI · Paper page
  103. Chytra, 2012, Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: A randomized open-label controlled trial, Crit. Care, 16, R113, 10.1186/cc11405 · DOI · Paper page
  104. Li, 2021, Short-course versus long-course antibiotic treatment in patients with uncomplicated gram-negative bacteremia: A systematic review and meta-analysis, J. Clin. Pharm. Ther., 46, 173, 10.1111/jcpt.13277 · DOI
  105. Haddad, 2022, Duration of antibiotic therapy in Gram-negative infections with a particular focus on multidrug-resistant pathogens, Curr. Opin. Infect. Dis., 10, 1097
  106. Babich, 2022, Duration of Treatment for Pseudomonas aeruginosa Bacteremia: A Retrospective Study, Infect. Dis. Ther., 11, 1505
  107. Fabre, 2019, Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?, Clin. Infect. Dis., 69, 2011, 10.1093/cid/ciz223 · DOI
  108. Olearo, 2020, Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients, Open Forum Infect. Dis., 7, ofaa246, 10.1093/ofid/ofaa246 · DOI
  109. Chastre, 2003, Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial, JAMA, 290, 2588, 10.1001/jama.290.19.2588 · DOI · Paper page
  110. Maharjan, 2022, Isolation and Characterization of Lytic Bacteriophage Against Multi-drug Resistant Pseudomonas aeruginosa, J. Nepal Health Res. Counc., 19, 717
  111. Dion, 2020, Phage diversity, genomics and phylogeny, Nat. Rev. Microbiol., 18, 125, 10.1038/s41579-019-0311-5 · DOI · Paper page
  112. Waters, 2017, Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa, Thorax, 72, 666, 10.1136/thoraxjnl-2016-209265 · DOI · Paper page
  113. Fong, 2017, Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients, Front. Cell. Infect. Microbiol., 7, 418, 10.3389/fcimb.2017.00418 · DOI · Paper page
  114. Guo, 2017, A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa, Front. Microbiol., 8, 293, 10.3389/fmicb.2017.00293 · DOI · Paper page
  115. Cook, 2021, INfrastructure for a PHAge REference Database: Identification of Large-Scale Biases in the Current Collection of Cultured Phage Genomes, PHAGE, 2, 214, 10.1089/phage.2021.0007 · DOI · Paper page
  116. Nordstrom, 2022, Genomic characterization of lytic bacteriophages targeting genetically diverse Pseudomonas aeruginosa clinical isolates, iScience, 25, 104372, 10.1016/j.isci.2022.104372 · DOI
  117. Cafora, 2019, Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model, Sci. Rep., 9, 1527, 10.1038/s41598-018-37636-x · DOI · Paper page
  118. Jennes, 2017, Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—A case report, Crit. Care, 21, 129, 10.1186/s13054-017-1709-y · DOI · Paper page
  119. Bach, 2022, Filamentous bacteriophage delays healing of Pseudomonas-infected wounds, Cell Rep. Med., 3, 100656, 10.1016/j.xcrm.2022.100656 · DOI
  120. Wright, 2009, A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy, Clin. Otolaryngol., 34, 349, 10.1111/j.1749-4486.2009.01973.x · DOI · Paper page
  121. Rhoads, 2009, Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial, J. Wound Care, 18, 237, 10.12968/jowc.2009.18.6.42801 · DOI · Paper page
  122. Rubalskii, E., Ruemke, S., Salmoukas, C., Boyle, E.C., Warnecke, G., Tudorache, I., Shrestha, M., Schmitto, J.D., Martens, A., and Rojas, S.V. (2020). Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery. Antibiotics, 9. · DOI
  123. Oechslin, 2017, Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas aeruginosa Infection in Endocarditis and Reduces Virulence, J. Infect. Dis., 215, 703
  124. Holger, 2022, Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing, J. Appl. Microbiol., 133, 1636, 10.1111/jam.15647 · DOI
  125. Chan, 2018, Phage treatment of an aortic graft infected with Pseudomonas aeruginosa, Evol. Med. Public Health, 2018, 60, 10.1093/emph/eoy005 · DOI · Paper page
  126. Duplessis, 2018, Refractory Pseudomonas Bacteremia in a 2-Year-Old Sterilized by Bacteriophage Therapy, J. Pediatr. Infect. Dis. Soc., 7, 253, 10.1093/jpids/pix056 · DOI
  127. Simner, 2022, Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis, JAC-Antimicrob. Resist., 4, dlac046, 10.1093/jacamr/dlac046 · doi:10.1093/jacamr/dlac046
  128. Khawaldeh, 2011, Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection, J. Med. Microbiol., 60, 1697, 10.1099/jmm.0.029744-0 · doi:10.1099/jmm.0.029744-0
  129. Racenis, 2022, Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis-A Case Report, Front. Med., 9, 851310, 10.3389/fmed.2022.851310 · doi:10.3389/fmed.2022.851310
  130. Aslam, 2019, Early clinical experience of bacteriophage therapy in 3 lung transplant recipients, Am. J. Transplant., 19, 2631, 10.1111/ajt.15503 · DOI · Paper page
  131. Chen, 2022, Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa, Biosci. Trends, 16, 158, 10.5582/bst.2022.01147 · doi:10.5582/bst.2022.01147
  132. Hoggarth, 2019, Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa, Drug Des. Devel. Ther., 13, 909, 10.2147/DDDT.S189847 · DOI
  133. Hart, 2022, Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections, Front. Microbiol., 13, 870104, 10.3389/fmicb.2022.870104 · DOI
  134. Adlbrecht, 2020, Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—A randomized clinical trial, Crit. Care, 24, 74, 10.1186/s13054-020-2792-z · doi:10.1186/s13054-020-2792-z
  135. Hauser, 2009, The type III secretion system of Pseudomonas aeruginosa: Infection by injection, Nat. Rev. Microbiol., 7, 654, 10.1038/nrmicro2199 · DOI · Paper page
  136. Sawa, 2014, Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: A review, Crit. Care Lond. Engl., 18, 668, 10.1186/s13054-014-0668-9 · DOI
  137. Luyt, 2012, Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized, double-blind, placebo-controlled trial, Crit. Care Med., 40, 2320, 10.1097/CCM.0b013e31825334f6 · DOI · Paper page
  138. Song, 2012, PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice, Eur. J. Clin. Microbiol. Infect. Dis., 31, 1837, 10.1007/s10096-011-1509-2 · DOI
  139. Lindorfer, 2001, Targeting of Pseudomonas aeruginosa in the Bloodstream with Bispecific Monoclonal Antibodies, J. Immunol., 167, 2240, 10.4049/jimmunol.167.4.2240 · DOI
  140. Lee, 2015, The hierarchy quorum sensing network in Pseudomonas aeruginosa, Protein Cell, 6, 26, 10.1007/s13238-014-0100-x · DOI · Paper page
  141. Nguyen, 2008, Pyopneumagen Group Quorum-sensing activity and related virulence factor expression in clinically pathogenic isolates of Pseudomonas aeruginosa, Clin. Microbiol. Infect., 14, 337, 10.1111/j.1469-0691.2007.01925.x · DOI
  142. Wu, 2004, Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice, J. Antimicrob. Chemother., 53, 1054, 10.1093/jac/dkh223 · DOI · Paper page
  143. Hoffmann, 2007, Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(−/−) mice, Antimicrob. Agents Chemother., 51, 3677, 10.1128/AAC.01011-06 · DOI · Paper page
  144. Adonizio, 2008, Inhibition of quorum sensing-controlled virulence factor production in Pseudomonas aeruginosa by South Florida plant extracts, Antimicrob. Agents Chemother., 52, 198, 10.1128/AAC.00612-07 · DOI · Paper page
  145. Smyth, 2010, Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis—A pilot randomized controlled trial, Pediatr. Pulmonol., 45, 356, 10.1002/ppul.21193 · DOI · Paper page
  146. Cotter, 2013, Bacteriocins—A viable alternative to antibiotics?, Nat. Rev. Microbiol., 11, 95, 10.1038/nrmicro2937 · DOI · Paper page
  147. Ali, 2011, Antagonistic effect of bacteriocin against urinary catheter associated Pseudomonas aeruginosa biofilm, N. Am. J. Med. Sci., 3, 367
  148. Snopkova, 2020, Prevalence of bacteriocins and their co-association with virulence factors within Pseudomonas aeruginosa catheter isolates, Int. J. Med. Microbiol., 310, 151454, 10.1016/j.ijmm.2020.151454 · doi:10.1016/j.ijmm.2020.151454

Cited by

See all 48

Metadata

Authors
Zakhour, J., Sharara, S. L., Hindy, J.-R., Haddad, S. F., & Kanj, S. S.
Venue
Antibiotics
Publisher
MDPI AG
Published
2022-10-18
Volume
11
Issue
10
Pages
1432
ISSN
2079-6382
Cited by
48
References
9
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis. https://app.cochat.ai/papers/10.3390/antibiotics11101432
The paper
Zakhour, J., Sharara, S. L., Hindy, J.-R., Haddad, S. F., & Kanj, S. S. (2022). Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis. Antibiotics. https://doi.org/10.3390/antibiotics11101432

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.